Search hospitals

>

Ohio

>

Cleveland

University Hospitals Cleveland Medical Center

Claim this profile

Cleveland, Ohio 44106

Global Leader in Lung Cancer

Global Leader in Cancer

Conducts research for Solid Tumors

Conducts research for Pancreatic Cancer

Conducts research for Heart Failure

927 reported clinical trials

125 medical researchers

Photo of University Hospitals Cleveland Medical Center in ClevelandPhoto of University Hospitals Cleveland Medical Center in ClevelandPhoto of University Hospitals Cleveland Medical Center in Cleveland

Summary

University Hospitals Cleveland Medical Center is a medical facility located in Cleveland, Ohio. This center is recognized for care of Lung Cancer, Cancer, Solid Tumors, Pancreatic Cancer, Heart Failure and other specialties. University Hospitals Cleveland Medical Center is involved with conducting 927 clinical trials across 1,225 conditions. There are 125 research doctors associated with this hospital, such as Pedro M. Barata, Afshin Dowlati, MD, Amit Mahipal, MD, and Lauren Henke, MD.

Area of expertise

1

Lung Cancer

Global Leader

University Hospitals Cleveland Medical Center has run 68 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 positive
2

Cancer

Global Leader

University Hospitals Cleveland Medical Center has run 46 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
KRAS positive

Top PIs

Clinical Trials running at University Hospitals Cleveland Medical Center

Ovarian Cancer

Lung Cancer

Crohn's Disease

Multiple Myeloma

Prostate Cancer

Esophageal Cancer

Psoriasis

Postoperative Pain

Non-Small Cell Lung Cancer

Colorectal Cancer

Image of trial facility.

Rina-S

for Ovarian Cancer

This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Heated Chemotherapy + Niraparib

for Ovarian Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at the time of iCRS (iCRS must achieve no gross residual disease or no disease \>1.0 cm in largest diameter) to receive HIPEC or no HIPEC. Patients randomized to HIPEC Arm will receive a single dose of cisplatin (100mg/m2 IP over 90 minutes at 42 C) as HIPEC. After postoperative recovery patients will receive standard post-operative platinum-based combination chemotherapy. Patients randomized to surgery only (No HIPEC Arm) will receive postoperative standard chemotherapy after recovery from surgery. Both groups will receive an additional 2-3 cycles of platinum-based combination chemotherapy per standard institutional guidelines +/- bevacizumab for a maximum total of 6 cycles of chemotherapy (neoadjuvant plus post-operative cycles) followed by niraparib individualized dosing +/- bevacizumab until progression or 36 months (if no evidence of disease).

Recruiting

2 awards

Phase 3

Image of trial facility.

ZN-c3

for Serous Carcinoma

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.

Recruiting

1 award

Phase 2

1 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University Hospitals Cleveland Medical Center?

Where is University Hospitals Cleveland Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does University Hospitals Cleveland Medical Center accept?

What awards or recognition has University Hospitals Cleveland Medical Center received?